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Background: The possibility of living well with a long-term condition has been identified as centrally relevant to
the needs of people living with dementia. Growing numbers of people with early-stage dementia are contributing
accounts that emphasise the benefits of actively engaging in managing the condition. Self-management
interventions share the common objectives of educating about the condition, optimising well-being, enhancing
control over the situation and enabling people to take more responsibility for managing the condition. Benefits of
such an approach can include improved knowledge, self-efficacy, health status, and better performance of
self-management behaviours. However, there is only preliminary evidence that people with early-stage dementia
can benefit from such interventions.
Methods: This feasibility study involves the development of a self-management group intervention for people with
early-stage Alzheimer’s disease, vascular dementia or mixed Alzheimer’s and vascular dementia. This study is a
single-site pilot randomised-controlled trial. Forty-two people with early stage dementia, each with a caregiver
(family member/friend), will be randomised to either the self-management group intervention or to treatment as usual.
The self-management group intervention will involve eight weekly sessions, each lasting 90 minutes, held at a
memory clinic in North Wales. All participants will be re-assessed three and six months post-randomisation. This
study is intended to supply an early evaluation of the self-management intervention so that a full scale trial may be
powered from the best available evidence. It will assess the feasibility of the intervention, the study design and the
recruitment strategies. It will estimate the parameters and confidence intervals for the research questions of interest.
The primary outcome of interest is the self-efficacy score of the person with dementia at three months
post-randomisation. Secondary outcomes for the person with dementia are self-efficacy at six months
post-randomisation and cognitive ability, mood and well-being at three and six months post-randomisation.
Secondary outcomes for caregivers are their distress and stress at three and six months post-randomisation.
The cost-effectiveness of the intervention will also be examined.
Discussion: This study will provide preliminary information about the feasibility, efficacy and cost-effectiveness of a
self-management group intervention for people in the early stages of dementia.
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Enabling self-management for people with long-term
health conditions is a continuing policy aim [1,2]. Self-
management has been defined as an ‘individual’s ability to
manage the symptoms, treatment, physical and psycho-
social consequences and life style changes inherent in liv-
ing with a chronic condition’ [3]. The possibility of living
well with a long-term condition has been identified as cen-
trally relevant to the needs of people with dementia and is
a key tenet of current policy [4]. In the absence of a cure
for dementia, there is a role for psychosocial interventions
in promoting optimal functioning [5].
Given the cognitive and functional decline involved in
dementia, self-management is most relevant in the early
stages, where the emphasis is on managing and living well
with the condition [6-8]. Offering suitable interventions to
people with early-stage dementia could delay admission to
residential care and add to the cost-effectiveness of ser-
vices; in other long-term health conditions, participation
in self-management programmes leads to a universal re-
duction in service costs that remains evident over time [9].
The findings from a review of self-management inter-
ventions in other long-term conditions have suggested
that self-management approaches provide benefits for
participants in terms of improved knowledge, perform-
ance of self-management behaviours, self-efficacy and
aspects of health status [3]. A recent review of various
self-management and educational interventions across a
range of conditions concluded that assisting people to
become more knowledgeable about and to develop basic
skills in managing their health condition could result
in physical and psychological benefits [10]. In terms
of health conditions, the paper concluded that self-
management had definite benefits for people suffering
from asthma and that this approach showed promise in
areas such as diabetes, epilepsy and mental health.
While there is evidence for the benefits of self-mana
gement interventions, the theoretical bases of these
interventions are often not explained [11]. The most
common conceptualisation of self-management [12] is
based on social cognitive theory [13,14]. Bandura pro-
posed that behaviour is influenced by goals, level of self-
efficacy, outcome expectations and various sociocultural
factors. Most empirical work has focused on the self-
efficacy component of this model. Self-efficacy is defined
as the person’s belief that s/he can perform a specific
action in a particular situation. Self-regulation offers an-
other theoretical basis for self-management. This theory
proposes that self-observation, self-evaluation and self-
reactions are the processes by which people learn to
deal with complex environments and develop problem-
solving strategies [15].
In relation to dementia, there is evidence to suggest
that people with early-stage dementia are usually able toidentify some issues that they would like to manage better
[16]. This offers an avenue for a sensitive and tailored ap-
proach to encourage individuals with early-stage dementia
to draw on their resources and on support from others
to make positive changes. Approaches such as support
groups [17], psychotherapy groups [18], goal-oriented re-
habilitation [19] and early-stage dyadic interventions [20]
support self-management skills by helping people to man-
age the present and future impact of the condition, iden-
tify and implement memory management strategies and
plan ahead to take control of legal, financial and health is-
sues. Therefore, there are preliminary, but limited, indica-
tions that people with early-stage dementia could benefit
from a more focused self-management approach.
While self-management approaches have common com-
ponents across conditions, these approaches are applied
with subtly different emphases depending on the nature of
the condition in question; for example, in diabetes there is
a focus on self-medicating and self-monitoring [21] while
the focus is on managing symptoms and promoting behav-
iour change in chronic obstructive pulmonary disease [22],
asthma [23] and rheumatism [24]. In order to conceptualise
self-management in early-stage dementia, it will be import-
ant to adapt the approach to take account of condition-
specific factors. However, there is limited evidence on
which to base the development of self-management ap-
proaches for people with dementia. One study explored
what people with dementia think should be included in
self-management interventions. Although few details were
provided about the participants who contributed, suggested
emphases included managing dementia alongside other
conditions, managing unexpected symptoms, and the im-
portance of maintaining meaningful roles [25]. Two further
papers have examined views about self-management held
by a range of respondents, including both health pro-
fessionals and people with dementia. Perceived barriers
to self-management included the impact of societal views
and public impressions and a general lack of information
[26]. Concepts of self-management echoed elements of
person-centred care and emphasised the ‘self ’ element
of self-management by focusing on managing life with
dementia rather than managing the dementia itself [27].
However, in these two papers the views of people with
dementia were not reported separately from the insights
gained from other respondents [26,27]. There is a need
for further in-depth investigation of the views of people
with dementia and caregivers to help formulate a de
mentia-specific approach to self-management, which
can then be evaluated in terms of feasibility, acceptabil-
ity and clinical efficacy, and ease of use by clinical
teams. The SMART study aims to address this need.
In the first phase of the SMART study, following an
initial qualitative investigation in which the perspectives
of people with dementia and caregivers were examined,
Quinn et al. Trials 2014, 15:74 Page 3 of 9
http://www.trialsjournal.com/content/15/1/74and a review of the literature on the theory and practice
of self-management in a range of conditions, a manual
for an eight-session group self-management intervention
for people with early-stage dementia was developed. The
intervention approach is based on self-regulation models
and social cognitive theory, and the overall aim is to en-
hance participants’ self-efficacy and problem-solving
skills through focusing on meaningful and relevant as-
pects of living with dementia. The pilot trial outlined in
this protocol is intended to provide preliminary evidence
about the feasibility and efficacy of the intervention so
that a subsequent full-scale randomised controlled trial
(RCT) may be powered from the best evidence available
in order to address the following objectives.
The primary objective is to evaluate the effectiveness of
the self-management intervention in improving self-efficacy
in people with dementia compared to treatment as usual
(TAU). The secondary objectives are to evaluate the effect-
iveness of the self-management intervention in (a) improv-
ing mood, well-being and cognitive test scores in people
with dementia compared to TAU; (b) decreasing caregiver
stress and general distress compared to TAU, and (c) esti-
mating the cost-effectiveness of the self-management inter-
vention compared to TAU and establishing whether it
results in a reduction in health service utilisation.
Methods
Design
This SMART study involves two phases, following the
development and feasibility/piloting phases of the Med-
ical Research Council guidelines for complex interven-
tions [28] and the present paper relates to phase II. In
phase I of the study we triangulated evidence from a sys-
tematic review and qualitative analysis of interviews with
people with dementia and caregivers to inform the de-
velopment of a protocol for a self-management group
intervention. In phase II we will evaluate the group
intervention in a single-site, single-blind pilot RCT com-
paring the self-management group with TAU. Outcomes
will be assessed at 3 and 6 months post-randomisation
by a researcher blinded to group allocation (Figure 1,
CONSORT diagram).
Setting and participants
The aim is to recruit 42 people with early-stage demen-
tia and their primary caregivers. The study will proceed
in three waves with approximately 14 participants in
each wave. The sample size will provide adequate statis-
tical power for a pilot evaluation of the self-management
group, and decisions about sample size have been in-
formed by the need to balance the number of partici-
pants required to provide an appropriate amount of
information for a pilot study with the number that it is
feasible to recruit within the study timescale. As this is apilot trial, particular note will be taken of recruitment and
retention rates so that a future definitive study may be
accurately powered. All participants will need to provide
informed consent. In order to be deemed to provide in-
formed consent, participants will have to demonstrate that
they can understand the study information, retain and
weigh up this information sufficiently to clearly communi-
cate their decision about participation, and clearly under-
stand the consequences of this decision.
Participants will be identified from a memory clinic in a
semi-rural area of North Wales. The inclusion criteria for
people with dementia are as follows: 1) participants must
be diagnosed with Alzheimer’s, vascular or mixed Alzhei-
mer’s and vascular dementia, according to ICD-10 criteria
[29] and in the early stages as indicated by a score of 20 or
more on the Mini-Mental State Examination [30]. These
diagnoses account for 89% of dementia diagnoses [31] and
rarer sub-types of dementia have been excluded here be-
cause they involve features that would require a specific
approach; 2) participants must be able to provide in-
formed consent; 3) participants may be either taking or
not taking acetyl-cholinesterase inhibitors or Memantine.
Participants receiving acetyl-cholinesterase inhibitors or
Memantine must have been stabilised on their current
dose for a minimum of one month prior to baseline as-
sessment, with no plan to change dosage or medication
during the course of the study. This is to ensure that
change is not confounded by medication effects, and 4)
participants must have a caregiver who is willing to par-
ticipate in the study. Caregivers may be spouses, partners,
siblings or adult children of people with early-stage de-
mentia who are involved in providing day-to-day support.
The exclusion criteria for people with dementia are as
follows: 1) a history of stroke, significant neurological or
psychiatric conditions (for example, psychosis) or brain in-
jury. These conditions may affect cognitive, emotional and
behavioural functioning and thus act as confounders;
2) current significant anxiety or depressive disorder that
would affect cognitive, emotional and behavioural func-
tioning and thus act as confounders, and 3) inability to
speak English sufficiently well to allow completion of the
assessment measures.
In addition, participants who are currently attending
other group-based psychosocial interventions will not be
enrolled in the study until these have been completed.
There are no specific exclusion criteria for caregivers;
any caregiver willing to take part together with the per-
son with dementia for whom she or he provides care will
be eligible for inclusion.
Outcome measures
Primary outcome measure
The primary outcome measure will be the scores recorded
by participants with dementia on the General Self-Efficacy
Figure 1 Consort diagram.
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GSES aims to measure a person’s broad and stable sense
of personal competence to deal effectively with a variety
of stressful situations. The current version of the scalecontains 10 items and participants can complete the meas-
ure in approximately 4 minutes. The GSES has high reli-
ability, stability, construct and factorial validity. It has
demonstrated convergent and discriminant validity [33].
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dementia at baseline, and three and six months post
randomisation
An important secondary outcome is the GSES score at 6
months post-randomisation, which will allow us to evalu-
ate whether the effects of the self-management group ex-
tend into the medium term.
Cognitive functioning The Addenbrooke’s Cognitive
Examination - III (ACE-III) [34] is a brief test sensitive to
the early stages of dementia. It measures cognitive ability
in five domains: attention (four items), memory (five
items), fluency (two items), language (eight items) and
visuo-spatial ability (five items). It is administered by the
researcher and can be completed in approximately 12–20
minutes. The ACE III has demonstrated convergent valid-
ity and internal reliability. It has high sensitivity and speci-
ficity in detecting cognitive problems [35].
Anxiety and depression The Hospital Anxiety and De-
pression Scale (HADS) [36,37] is a self-report measure
of symptoms of anxiety and depression. All symptoms
that can also relate to physical disorder, such as fatigue,
have been excluded, which makes the scale particularly
suited to older adults who may experience other medical
conditions. It contains 14 items each answered on a 4-
point Likert scale (0 = not at all, 3 = very often indeed)
though some items are reverse-scored. Subtotals are de-
rived for anxiety and depression. The HADS has been
previously employed and validated in people with de-
mentia [38].
Well-being/risk The Clinical Outcomes in Routine
Evaluation - Outcome Measure (CORE-OM) [39] is a
self-report measure of problem severity. It contains 34
items which are scored on a 4-item Likert scale (0 = not
at all, 4 = most or all of the time). It covers four do-
mains: wellbeing, social functioning, problems/symp-
toms, and risk to self and risk to others, as well as
providing a global distress score. The CORE-OM has
good internal consistency and test-retest reliability. It
also has good convergent validity and shows sensitivity
to change [39].
Health-related quality of life The EQ-5D-3L [40,41]
was designed to measure health-related quality of life.
The assessment has five questions covering five domains
(mobility, self-care, usual activities, pain/discomfort and
anxiety/depression). Each item is answered on a 3-point
scale (level 1 = no problems, level 3 = unable to do or
extreme problem doing). A visual analogue scale is also
incorporated into the measure and respondents indicate
how good their health is at the time of rating on a 0-to-
100 scale, with the anchor points being worst (0) andbest (100) imaginable health state. The EQ-5D-3L has
been used in a UK sample of people with dementia, in-
cluding early-stage dementia [42]. A systematic review
of recent studies using the EQ-5D-3L with people with
dementia reported good feasibility and reliability of the
instrument [43]. In a French sample of people with de-
mentia the measure has demonstrated acceptability and
construct validity, although inter-rater agreement is lim-
ited [44]. In other populations the EQ-5D-3L has good
test-retest reliability [41].Quality of life The instrument, the ICEpop CAPability
Measure for Older People (ICECAP-O) [45] focuses on a
broader sense of wellbeing. It covers the attributes of qual-
ity of life that were rated as important by a UK sample of
older people. It measures five attributes (attachment, role,
enjoyment, security and control) on a 4-point scale (4 = I
can have/I am able, 1 = I cannot have/I am not able). This
scale has demonstrated acceptability in a sample of UK
older adults and there is initial evidence of construct valid-
ity [46].Service use The Client Socio-Demographic and Service
Receipt Inventory (CSRI) [47] asks participants about
their use of health and social services over the last three
months. They are asked to report the frequency and in-
tensity of their service use. It takes approximately 20 mi-
nutes to complete. The CSRI has adequate concurrent
validity [47]. In the current study, if necessary, the care-
giver will be asked to help the person with dementia to
complete this measure.Secondary outcome measures completed by caregivers at
baseline, and three and six months post-randomisation
Caregiver distress The Neuropsychiatric Inventory
Questionnaire (NPI-Q) [48] assesses behavioural and
psychological symptoms and covers 12 domains. The 12
items are scored for severity (3-point scale) and for the
degree of caregiver distress experienced (5-point scale).
It is a self-report measure and can be completed in ap-
proximately 5 minutes. The NPI-Q has good internal
consistency and test-retest reliability. It has demon-
strated construct validity [48].Caregiver stress The Relative Stress Scale (RSS) [49] is
a self-report measure of caregivers’ levels of stress relat-
ing to caring for their relative. There are 15 items an-
swered on a 5-point Likert scale (0 = not at all, 4 =
always/considerably). The scale comprises three sub-
scales: personal distress, life upset from caregiving and
negative feelings. The RSS has factorial validity and ad-
equate internal consistency [50].
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will be used (see above).
Quality of life The ICECAP-O [45] will be used (see
above).
Service use The CSRI [47] will be used (see above).
Post-intervention interview Participant dyads rando-
mised to the self-management group will be invited to
take part in a 20-minute semi-structured interview to
explore their perceptions and views of the group. This
interview will be conducted by the researcher and will
be audio-recorded.
Intervention
The self-management group intervention will involve
eight 90-minute sessions held at weekly intervals at a
memory clinic in North Wales. It will be led by two
members of the clinical team who will be trained to ad-
minister the intervention by the research team, with on-
going access to support during the study. Up to seven
people with dementia will attend each group, and care-
givers (a relative or friend of each participating person
with dementia) will be invited to attend the first and
final sessions. Caregivers may also, if they wish, join the
group at the end of each meeting to hear an overview of
the theme that has been covered. Participants will be
invited to share only personal information that they
are comfortable disclosing during the self-management
group. Each attendee will receive a booklet which will
cover the content of each session: this will allow space
for additional notes and comments to be made and the
person with dementia can share this resource with the
caregiver between sessions. Participants attending the
self-management group will continue with all other care
services they are receiving.
There will be a flexible approach to the organisation and
structure of sessions. Each session will cover a particular
theme and participants will discuss the theme with each
other and the facilitators. Within each theme participants
will be able to focus on aspects that are meaningful to
group members. Session themes will cover an orientation
to the group and information sharing, enjoying hobbies,
activities and interests, staying well, practical ways to man-
age memory difficulties, maintaining relationships and so-
cial networks, planning for the future, coping skills and
accessing local resources. The group will be facilitated in
an informal manner and time will be provided for more
social activities. The facilitators will keep a record of the
number of intervention sessions attended by each partici-
pant. The facilitators will also write a summary of each
session incorporating their impressions of participants’ in-
volvement in the meeting.Comparison condition: treatment as usual
Participants randomised to TAU will continue to receive
the normal services provided by the memory clinic.
These services include a regular nurse-led clinical review
and access to services such as psychiatry, occupational
therapy and social services as needed. Using TAU as a
comparator condition ensures that all participants re-
ceive needed services.
Procedure
Potential participants will be invited to take part via an
invitation letter or via personal contact from a member
of the clinical team. Posters and leaflets advertising the
study will be displayed at the memory clinic and groups
that make use of the service facilities, such as the local
Alzheimer’s café, will receive information about the
study. As this is a pilot study, a range of recruitment
methods is envisaged to inform future multi-centre tri-
als. People interested in taking part will be contacted by
a researcher who can provide more information about
the study and answer any questions. If the person is in-
terested in taking part in the study the researcher will
arrange a meeting. If the person consents to take part in
the study, the researcher will make final eligibility checks
and carry out the baseline assessments. Participants will
be allowed to pace these assessment visits according to
their needs. For instance, short breaks will be permis-
sible if participants are fatigued and if necessary two
visits will be made to complete the assessments at each
data point.
Eligible, consenting participants will be randomised to
receive either the self-management group intervention
or TAU after baseline assessments. Randomisation will
be conducted by the North Wales Organisation for Ran-
domised Trials in Health (NWORTH). Randomisation
will be undertaken using a computer-based algorithm.
Randomisation will be balanced (one: one dynamic allo-
cation) [51] and will be stratified for mini-mental state
examination score (20 to 24, 25 to 25+) and gender.
Follow-up assessments will occur at 3 and 6 months
post-randomisation and will be undertaken by a re-
searcher blinded to group allocation. There will be no
unblinding of the researcher, and participants will be
asked not to tell the researcher whether they attended
the group. To assist retention in the study, appointments
will be prescheduled with participants, and reminders of
upcoming meetings will be sent. Participants who attend
the self-management group will additionally be invited
to take part in a post-intervention interview to feed back
their experiences of attending the group.
Analysis
Data will be entered into IBM SPSS Statistics v20 and
checked to ensure that accuracy is within acceptable
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at least two data points will be included in the analysis.
All available data will be included and an intention-to-
treat analysis will be conducted. If an outcome measure
has less than 20% missing responses, missing data will
pro-rated with the participant’s mean item score to allow
a calculation of the total score. If an outcome measure
has more than 20% missing responses, methods of mul-
tiple imputation will be explored and a range of sensitiv-
ity analyses will be performed to inform the main RCT.
As this is a pilot study all outcomes will be reported and
particular note will be taken of effect sizes and confi-
dence intervals.
Analysis of covariance (ANCOVA) using baseline scores
and stratification variables as covariates will compare
group outcomes with regard to the primary outcome, the
self-efficacy scores of people with dementia at 3 months
post-randomisation. Secondary outcomes will be analysed
similarly and confidence intervals will be quoted for all
parameter estimates. The Bonferroni correction for mul-
tiple testing will not be made as this is a pilot exploratory
study to estimate potential effect sizes rather than a
strictly hypothesis-testing experimental design. The post-
intervention interviews will be analysed using thematic ana-
lysis to explore and summarise participants’ experience of
the intervention. This analysis will be undertaken independ-
ently by members of the research team. Inter-rater reliabil-
ity will be addressed by having a random selection of 20%
of transcripts coded by two raters so that differences can be
discussed and resolved. If inter-rater reliability reaches 80%
or more, then the remainder of transcripts can be coded by
a single rater. If not, a further 20% of transcripts will be
coded by both raters and the process repeated.
An economic evaluation will investigate the incremental
cost-effectiveness of the self-management group compared
with TAU. Costs for the group will be calculated from
a public-sector multi-agency perspective. Primary and
secondary care health service use will be collected using
the CSRI and costs will be calculated using national unit
costs [52,53]. A cost-utility analysis using the EQ-5D-3L
will generate a cost per quality-adjusted life-year and cost-
effectiveness acceptability curve for comparison with the
National Institute for Health and Care Excellence ceiling
of £20,000 to £30,000 [54]. A secondary exploratory cost-
effectiveness analysis will be undertaken using the GSES
and ICECAP-O as the measures of effectiveness. As this is
a pilot trial with a relatively small sample size, the tree-age
modelling package will be utilised to map a decision ana-
lytic model to inform data collection for the economic
evaluation of a future definitive multi-centre study.
Ethical approval
The study has ethical approval from the North Wales
Research Ethics Committee-West (Reference: 13/WA/0174) and the School of Psychology Ethics Committee,
Bangor University. All data, including interview tran-
scripts, will be anonymised. Participants will also be
made aware that they can omit any questions they do
not wish to answer during the assessment sessions and
will be made aware of their right to withdraw from the
study at any point. Participant information will be stored
securely at the university site and all electronic data will
be encrypted. Anonymised data will be kept for up to 5
years after the end of the study. Only the research team
will have access to the full dataset.
Discussion
At present the evidence base for self-management in
people with early-stage dementia is minimal. Given the
potential of people with early-stage dementia to develop
self-management skills, it is timely to consider how health
services may support this process. This study will imple-
ment a self-management group intervention and evaluate
its efficacy and cost-effectiveness in a pilot randomised
controlled trial, conducted within a National Health Ser-
vice memory clinic in the UK. This will provide prelimin-
ary evidence about the usefulness and acceptability of
such an approach to people with early-stage dementia and
their caregivers, which will serve as a basis for further
research.
Trial status
The trial is ongoing and is due to finish in December
2014.
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